{"created":"2023-07-18T05:23:36.425707+00:00","id":2019931,"links":{},"metadata":{"_buckets":{"deposit":"d599bef7-6171-4ff9-b799-5de66f836a3c"},"_deposit":{"created_by":8,"id":"2019931","owner":"8","owners":[8],"pid":{"revision_id":0,"type":"depid","value":"2019931"},"status":"published"},"_oai":{"id":"oai:u-ryukyu.repo.nii.ac.jp:02019931","sets":["1642838163960:1642838338003","1642838403551:1642838409905"]},"author_link":[],"item_1617186331708":{"attribute_name":"Title","attribute_value_mlt":[{"subitem_1551255647225":"Development and acceptability of a decision aid for chronic insomnia considering discontinuation of benzodiazepine hypnotics","subitem_1551255648112":"en"}]},"item_1617186419668":{"attribute_name":"Creator","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Aoki, Yumi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Takaesu, Yoshikazu","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Suzuki, Masahiro","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Okajima, Isa","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Takeshima, Masahiro","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Shimura, Akiyoshi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Utsumi, Tomohiro","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Kotorii, Nozomu","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Yamashita, Hidehisa","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Kuriyama, Kenichi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Watanabe, Norio","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Mishima, Kazuo","creatorNameLang":"en"}]}]},"item_1617186476635":{"attribute_name":"Access Rights","attribute_value_mlt":[{"subitem_1522299639480":"open access","subitem_1600958577026":"http://purl.org/coar/access_right/c_abf2"}]},"item_1617186499011":{"attribute_name":"Rights","attribute_value_mlt":[{"subitem_1522650717957":"en","subitem_1522651041219":"© 2021 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology."},{"subitem_1522650717957":"en","subitem_1522650727486":"https://creativecommons.org/licenses/by-nc-nd/4.0/","subitem_1522651041219":"This is an open access article under the terms of the Creative Commons Attribution-NonCommercial- NoDerivs License"}]},"item_1617186609386":{"attribute_name":"Subject","attribute_value_mlt":[{"subitem_1522299896455":"en","subitem_1522300014469":"Other","subitem_1523261968819":"benzodiazepines"},{"subitem_1522299896455":"en","subitem_1522300014469":"Other","subitem_1523261968819":"chronic insomnia"},{"subitem_1522299896455":"en","subitem_1522300014469":"Other","subitem_1523261968819":"decision aid, hypnotics"},{"subitem_1522299896455":"en","subitem_1522300014469":"Other","subitem_1523261968819":"shared decision-making"}]},"item_1617186626617":{"attribute_name":"Description","attribute_value_mlt":[{"subitem_description":"Aim: To describe the development and acceptability of a decision aid (DA) for chronic insomnia considering discontinuation of benzodiazepine (BZD) and benzodiazepine receptor agonist (BZRA) hypnotics, and if discontinuing, tapering with or without cognitive behavioral therapy for insomnia (CBT-I).\nMethods: We reviewed relevant literature describing chronic insomnia to identify options. We used the results of the systematic review and meta-analysis conducted previously to determine the related outcomes of two options: discontinuation of BZD/BZRA hypnotics by gradual tapering alone and discontinuation of BZD/BZRA hypnotics by gradual tapering with CBT-I. We then developed a prototype of DA following the International Patient Decision Aid Standards. A mixed methods survey was conducted to assess the acceptability among patients and healthcare providers.\nResults: The prototype consisted of a description of insomnia, options of continuing or discontinuing BZD/BRZA hypnotics (if discontinuing, the options of tapering hypnotics with or without CBT-I), pros and cons of each option, and a value clarification","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_1617186643794":{"attribute_name":"Publisher","attribute_value_mlt":[{"subitem_1522300295150":"en","subitem_1522300316516":"© 2021 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology."}]},"item_1617186702042":{"attribute_name":"Language","attribute_value_mlt":[{"subitem_1551255818386":"eng"}]},"item_1617186920753":{"attribute_name":"Source Identifier","attribute_value_mlt":[{"subitem_1522646500366":"EISSN","subitem_1522646572813":"2574-173X"}]},"item_1617186941041":{"attribute_name":"Source Title","attribute_value_mlt":[{"subitem_1522650068558":"en","subitem_1522650091861":"Neuropsychopharmacology Reports"}]},"item_1617187056579":{"attribute_name":"Bibliographic Information","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2021-11-22","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"20","bibliographicPageStart":"10","bibliographicVolumeNumber":"42"}]},"item_1617258105262":{"attribute_name":"Resource Type","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_1617265215918":{"attribute_name":"Version Type","attribute_value_mlt":[{"subitem_1522305645492":"VoR","subitem_1600292170262":"http://purl.org/coar/version/c_970fb48d4fbd8a85"}]},"item_1617353299429":{"attribute_name":"Relation","attribute_value_mlt":[{"subitem_1522306287251":{"subitem_1522306382014":"DOI","subitem_1522306436033":"https://doi.org/10.1002/npr2.12219"}}]},"item_1617605131499":{"attribute_name":"File","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2023-07-18"}],"filename":"A_No42p10.pdf","filesize":[{"value":"590 KB"}],"url":{"url":"https://u-ryukyu.repo.nii.ac.jp/record/2019931/files/A_No42p10.pdf"},"version_id":"e8a3591d-550c-47ae-a2a1-3b72c0329d8d"}]},"item_title":"Development and acceptability of a decision aid for chronic insomnia considering discontinuation of benzodiazepine hypnotics","item_type_id":"59","owner":"8","path":["1642838338003","1642838409905"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2023-07-18"},"publish_date":"2023-07-18","publish_status":"0","recid":"2019931","relation_version_is_last":true,"title":["Development and acceptability of a decision aid for chronic insomnia considering discontinuation of benzodiazepine hypnotics"],"weko_creator_id":"8","weko_shared_id":-1},"updated":"2023-08-03T05:44:57.855549+00:00"}